Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Helus Pharma (NASDAQ:HELP)

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Helus Pharma (NASDAQ:HELP)

Helus Pharma (NASDAQ:HELP) shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder (GAD). Helus Pharma was originally founded as Cybin Inc. in 2019. Anxiety Disorder Data In the Phase 2 study, 36 patients were randomized to receive either HLP004 or a placebo. Results indicated a 10.4-point improvement in anxiety symptoms bey…

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects sustained through at

Helus Pharma's stock slides after psychedelic drug data face questions over dosing

Mid-stage data from Helus Pharma’s psychedelic drug raised questions about the doses the company picked for treating anxiety. Two doses — one 10 times higher than the other — led to virtually the same efficacy results. ...